1804P APEX-01: first-in-human phase I/II study of ARX517 an anti-prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with …
J Shen, R Pachynski, LT Nordquist, N Adra… - Annals of …, 2023 - annalsofoncology.org
Background ARX517 is a novel ADC composed of a fully humanized anti-PSMA mAb
conjugated to amberstatin-269, a potent tubulin inhibitor. ARX517 was designed to reduce …
conjugated to amberstatin-269, a potent tubulin inhibitor. ARX517 was designed to reduce …
MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.
JS De Bono, MT Fleming, JSZ Wang, R Cathomas… - 2020 - ascopubs.org
99 Background: MEDI3726 is an ADC targeting PSMA. Once bound to PSMA and
internalized, the released pyrrolobenzodiazepine dimer toxin crosslinks DNA and triggers …
internalized, the released pyrrolobenzodiazepine dimer toxin crosslinks DNA and triggers …
Abstract CT121: ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose escalation and dose expansion study …
Background: Targeted therapies against prostate-specific membrane antigen (PSMA) have
exhibited promising antitumor activity in prostate cancer. With the FDA's approval of (177) Lu …
exhibited promising antitumor activity in prostate cancer. With the FDA's approval of (177) Lu …
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer …
DP Petrylak, DC Smith, LJ Appleman, MT Fleming… - 2014 - ascopubs.org
5023 Background: PSMA expression on prostate cancer cells provides a rationale for ADC
therapy. PSMA is a clinically validated target. PSMA ADC is a fully human antibody to PSMA …
therapy. PSMA is a clinically validated target. PSMA ADC is a fully human antibody to PSMA …
Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer …
MC Markowski, D Kilari, MA Eisenberger, RR McKay… - 2021 - ascopubs.org
TPS5094 Background: CCW702 is a novel bispecific antibody comprised of a small
molecule imaging agent ligand (DUPA) with specificity for prostate specific membrane …
molecule imaging agent ligand (DUPA) with specificity for prostate specific membrane …
Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients with progressive metastatic …
MI Milowsky, M Galsky, J Lewin, CP Rozario… - Journal of Clinical …, 2005 - ascopubs.org
4615 Background: MLN2704 is an immunoconjugate that delivers the maytansinoid
antimicrotubule agent DM1 directly to prostate cancer cells via the PSMA-targeted …
antimicrotubule agent DM1 directly to prostate cancer cells via the PSMA-targeted …
A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer …
DP Petrylak, DC Smith, LJ Appleman, MT Fleming… - 2014 - ascopubs.org
83 Background: The abundant expression of prostate-specific membrane antigen (PSMA)
on prostate cancer cells provides a rationale for antibody therapy. PSMA antibody drug …
on prostate cancer cells provides a rationale for antibody therapy. PSMA antibody drug …
A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate …
DP Petrylak, NJ Vogelzang, GS Chatta, MT Fleming… - 2015 - ascopubs.org
144 Background: PSMA is a validated target that is overexpressed selectively on prostate
cancer cells. PSMA ADC is a fully human IgG1 antibody conjugated to the microtubule …
cancer cells. PSMA ADC is a fully human IgG1 antibody conjugated to the microtubule …
41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and …
S Zhang, D Mills, JY Kim, N Knudsen… - Annals of …, 2023 - annalsofoncology.org
Background Prostate cancer is the second leading cause of cancer death among men in the
United States. Metastatic castration-resistant prostate cancer (mCRPC) is an advanced …
United States. Metastatic castration-resistant prostate cancer (mCRPC) is an advanced …
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate …
LK Skidmore, D Mills, JY Kim, NA Knudsen… - Molecular Cancer …, 2024 - aacrjournals.org
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced disease in which
patients ultimately fail standard-of-care androgen deprivation therapies and exhibit poor …
patients ultimately fail standard-of-care androgen deprivation therapies and exhibit poor …
相关搜索
- psma adc prostate cancer
- membrane antigen antibody drug
- membrane antigen prostate cancer
- psma and cd3 molecule antibody
- failure of abiraterone antibody drug
- membrane antigen immunoconjugate mln2704
- membrane antigen abiraterone or enzalutamide
- psma and cd3 prostate cancer
- molecule antibody prostate cancer
- bispecific antibody prostate cancer
- abiraterone or enzalutamide antibody drug
- membrane antigen failure of abiraterone